LEADER 01209nam--2200385---450- 001 990000973180203316 005 20090205154237.0 010 $a88-464-3315-7 035 $a0097318 035 $aUSA010097318 035 $a(ALEPH)000097318USA01 035 $a0097318 100 $a20020221d2002----km-y0itay0103----ba 101 $aita 102 $aIT 105 $a||||||||001yy 200 1 $aQualità "alla Carta"$everso l'eccellenza con Carta dei servizi$fBruno Susio, Giovanni Barbieri$g[prefazione di Alberto Galgano] 210 $aMilano$cF.Angeli$dcopyr.2002 215 $a127 p.$d23 cm 225 2 $aAzienda moderna$v476 410 0$12001$aAzienda moderna 606 0 $aServizi pubblici$xControllo di qualità 676 $a363.60685 700 1$aSUSIO,$bBruno$0117621 701 1$aBARBIERI,$bGiovanni$071551 912 $a990000973180203316 951 $a363.606 SUS 1 (IEP X 164$b10212 E.C.$cIEP X$d00080443 959 $aBK 969 $aECO 979 $aPAOLA$b90$c20020221$lUSA01$h1156 979 $c20020403$lUSA01$h1739 979 $aPATRY$b90$c20040406$lUSA01$h1707 979 $aRSIAV1$b90$c20090205$lUSA01$h1542 996 $aQualità "alla carta"$9507379 997 $aUNISA LEADER 01522nam2-2200445---450 001 990003112690203316 005 20200708115733.0 010 $a88-14-12895-2 035 $a000311269 035 $aUSA01000311269 035 $a(ALEPH)000311269USA01 035 $a000311269 100 $a20080529d2008----km-y0itay50------ba 101 $aita 102 $aIT 105 $a||||||||001yy 200 1 $a<<1.:>> <> principi generali; I contratti pubblici; I soggetti$fdiretto da Maria Alessandra Sandulli, Rosanna De Nictolis, Roberto Garofoli 210 $aMilano$cGiuffré$d2008 215 $aXXXVII, 734 p.$d224 cm 461 1$1001000311267$12001$aTrattato sui contratti pubblici 606 0 $aContratti pubblici$2BNCF 676 $a346.45023 702 1$aSANDULLI,$bMaria ALESSANDRA 702 1$aDE NICTOLIS,$bRosanna 702 1$aGAROFOLI,$bRoberto 801 0$aIT$bsalbc$gISBD 912 $a990003112690203316 951 $aXXIV.3.H 82/1 (IG V 1373/1)$b58686 G.$cIG V$d00210965 959 $aBK 969 $aGIU 979 $aCHIARA$b90$c20080529$lUSA01$h1511 979 $aCHIARA$b90$c20080529$lUSA01$h1511 979 $aCHIARA$b90$c20080529$lUSA01$h1515 979 $aCHIARA$b90$c20080529$lUSA01$h1519 979 $aCHIARA$b90$c20080529$lUSA01$h1526 979 $aCHIARA$b90$c20080529$lUSA01$h1539 979 $aCHIARA$b90$c20080529$lUSA01$h1547 979 $aRSIAV4$b90$c20090612$lUSA01$h1208 996 $aPrincipi generali. I contratti pubblici. I soggetti$9808409 997 $aUNISA LEADER 05351nam 2200685 a 450 001 9910806296203321 005 20200520144314.0 010 $a9786612123009 010 $a9781282123007 010 $a1282123009 010 $a9780470698921 010 $a0470698926 010 $a9780470698389 010 $a0470698381 035 $a(CKB)1000000000687605 035 $a(EBL)470609 035 $a(OCoLC)609849592 035 $a(SSID)ssj0000354362 035 $a(PQKBManifestationID)11277480 035 $a(PQKBTitleCode)TC0000354362 035 $a(PQKBWorkID)10313208 035 $a(PQKB)10737552 035 $a(MiAaPQ)EBC470609 035 $a(Au-PeEL)EBL470609 035 $a(CaPaEBR)ebr10297729 035 $a(CaONFJC)MIL212300 035 $a(Perlego)2769675 035 $a(EXLCZ)991000000000687605 100 $a20000329d2002 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aInsulin resistance $ea clinical handbook /$fAndrew J. Krentz 205 $a1st ed. 210 $aOxford ;$aMalden, Mass. $cBlackwell Science$dc2002 215 $a1 online resource (202 p.) 300 $aDescription based upon print version of record. 311 08$a9780632056620 311 08$a0632056622 320 $aIncludes bibliographical references and index. 327 $aInsulin Resistance A Clinical Handbook; Contents; Preface; About the author; Acknowledgements; 1 Pathophysiology of insulin resistance; 1.1 Introduction; 1.2 Normal physiology; 1.2.1 Hormonal regulation of metabolism; 1.2.2 The insulin receptor; 1.2.3 Post-binding events; 1.2.4 Glucose metabolism; 1.2.5 Lipid metabolism; 1.2.6 Protein metabolism; 1.2.7 Ion transport; 1.3 The concept of insulin resistance; 1.3.1 Early studies of insulin action; 1.3.2 Radioimmunoassays for insulin; 1.4 Definitions of insulin resistance; 1.5 Assessment of insulin action in vivo 327 $a1.5.1 Fasting insulin concentration1.5.2 Dynamic techniques-endogenous insulin; 1.5.3 Dynamic techniques-exogenous insulin; 1.5.4 Mathematical modelling techniques; 1.5.5 Insulin suppression test; 1.5.6 Hyperinsulinaemic euglycaemic clamp technique; 1.5.7 Complementary techniques; 1.6 Mechanisms of insulin resistance; 1.6.1 Genetic defects; 1.6.2 Acquired forms of insulin resistance; 1.6.3 Fetal origins hypothesis; 1.7 Further reading; 2 Insulin resistance in clinical medicine; 2.1 Clinical features; 2.2 Factors influencing insulin sensitivity; 2.2.1 Normal variation in insulin action 327 $a2.2.2 Sex2.2.3 Age; 2.2.4 Physical exercise; 2.2.5 Tobacco; 2.2.6 Alcohol; 2.3 Physiological states of insulin resistance; 2.3.1 Puberty; 2.3.2 Pregnancy; 2.3.3 Menstrual cycle; 2.3.4 The menopause; 2.4 Severe insulin-resistance syndromes; 2.5 Insulin resistance and cardiovascular risk; 2.5.1 Syndrome X; 2.5.2 Obesity; 2.5.3 Regional adiposity; 2.5.4 Impaired glucose tolerance; 2.5.5 Type 2 diabetes mellitus; 2.5.6 Essential hypertension; 2.5.7 Dyslipidaemia; 2.5.8 Endothelial dysfunction; 2.5.9 Microalbuminuria; 2.5.10 Hyperuricaemia; 2.5.11 Impaired fibrinolysis 327 $a2.5.12 Polycystic ovary syndrome2.5.13 Non-alcoholic steatohepatitis; 2.6 Other disorders associated with insulin resistance; 2.6.1 Counter-regulatory hormone secretion; 2.6.2 Endocrinopathies; 2.6.3 Chronic renal failure; 2.6.4 Hepatic cirrhosis; 2.6.5 Cardiac failure; 2.7 Miscellaneous inherited disorders; 2.8 Drug-induced insulin resistance; 2.9 Further reading; 3 Management of insulin resistance and associated conditions; 3.1 Non-pharmacological measures; 3.1.1 Medical nutrition therapy; 3.1.2 Physical activity; 3.1.3 Alcohol; 3.1.4 Tobacco; 3.2 Drugs for type 2 diabetes; 3.2.1 Biguanides 327 $a3.2.2 Thiazolidinediones3.2.3 Sulphonylureas; 3.2.4 Meglitinide analogues; 3.2.5 ?-Glucosidase inhibitors; 3.2.6 Insulin; 3.3 Antiobesity drugs; 3.3.1 Sibutramine; 3.3.2 Orlistat; 3.3.3 Leptin; 3.2.4 ?3-adrenocepter agonists; 3.4 Lipid-modifying drugs; 3.4.1 Fibric acid derivatives; 3.4.2 Acipimox; 3.4.3 Statins; 3.4.4 Omega-3 fatty acids; 3.5 Antihypertensive drugs; 3.2.4 ?-adrenocepter agonists; 3.5.2 Calcium-channel blockers; 3.5.3 Angiotensin converting enzyme inhibitors; 3.5.4 Angiotensin II receptor antagonists; 3.5.5 ?1-Receptor blockers; 3.5.6 Selective imidazoline receptor agonists 327 $a3.5.7 Aspirin 330 $aInsulin resistance, defined as a reduced biological action of insulin, has emerged as a major factor in the development and progression of a number of common non-communicable diseases in man. The role of insulin resistance in the aetiology of type 2 diabetes is particularly well-established. However, insulin resistance has also come to be regarded as a key component of a broader syndrome of common metabolic defects that conspire to increase the risk of atherosclerotic coronary heart disease. The ramifications of insulin resistance now embrace many different medical specialties. The obje 606 $aInsulin resistance$vHandbooks, manuals, etc 615 0$aInsulin resistance 676 $a616.4/6207 700 $aKrentz$b Andrew J$0937191 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910806296203321 996 $aInsulin resistance$92110860 997 $aUNINA